Stephens & Co. Maintains Overweight on Amrize, Lowers Price Target to $54

Benzinga Newsdesk www.benzinga.com Negative 76.3%

Neg 76.3% Neu 0% Pos 0%

Stephens & Co. analyst Trey Grooms maintains Amrize (NYSE:AMRZ) with a Overweight and lowers the price target from $65 to $54.